The phase 2 trial, FRAMES, is expected to start patient enrollment in the coming weeks in the
Hospital La Paz (Madrid), lead by Dr. Francisco Javier Rodríguez de Rivera. The company is
also working to open additional sites at medical institutions in Belgium, Germany and France.
The upcoming trial is designed to be double-blind and placebo-controlled with the aim of
assessing the efficacy and safety of MIN-102 in Friedreich’s Ataxia patients. For more information please find the press release here.